Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

By sjmartinez • September 12, 2024

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Epub ahead of print. PMID: 39260522.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel

Freedland SJ, Aronson W, Asher A, Golant M, Lemke E, Morgans AK, Morris D, Sullivan C, Sutton J, Thomson CA, Twardowski P, Wefel JS, Winters-Stone[...]

A Multicomponent Approach to Screening for Dementia in Older Hospitalized Patients

Tan ZS, Qureshi N, Sicotte NL, Hirsch D, Escovedo C, Spivack E, Nasmyth MC, Gonzales M, Kremen SA, Nuckols TK, Mafi J, McFadden J, Roberts[...]